CXCL14 expression and potential function in pancreatic cancer

Cancer Letters

Volumn 259, Issue 2, 2008, Pages 209-217

  Wente, Moritz N ^a   Mayer, Christine ^a   Gaida, Matthias M ^a   Michalski, Christoph W ^a,b   Giese, Thomas ^a   Bergmann, Frank ^a   Giese, Nathalia A ^a   Büchler, Markus W ^a   Friess, Helmut ^a,b  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

CXC chemokines; CXCL14; Invasion; Pancreatic cancer

Indexed keywords

CXCL14 CHEMOKINE; GELATINASE A; TRANSCRIPTION FACTOR RELA; VASCULOTROPIN;

ADULT; AGED; ANGIOGENESIS; ARTICLE; CANCER GROWTH; CANCER INVASION; CELL VIABILITY; CHEMOSENSITIVITY; CHRONIC PANCREATITIS; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOLOCALIZATION; MALE; METASTASIS; PANCREAS CANCER; PATHOGENESIS; PRIORITY JOURNAL; RECEPTOR UPREGULATION; REGULATORY MECHANISM;

AGED; ANTIMETABOLITES, ANTINEOPLASTIC; CELL LINE, TUMOR; CELL SURVIVAL; CHEMOKINES, CXC; DEOXYCYTIDINE; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MATRIX METALLOPROTEINASE 2; MIDDLE AGED; NEOPLASM INVASIVENESS; PANCREATIC NEOPLASMS; RNA, MESSENGER; TIME FACTORS; TRANSCRIPTION FACTOR RELA; UP-REGULATION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 37049017767     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2007.10.021     Document Type: Article

References (36)

1. Li D., Xie K., Wolff R., and Abbruzzese J.L. Pancreatic cancer. Lancet 363 (2004) 1049-1057
2. Friess H., Ding J., Kleeff J., Fenkell L., Rosinski J.A., Guweidhi A., Reidhaar-Olson J.F., Korc M., Hammer J., and Buchler M.W. Microarray-based identification of differentially expressed growth- and metastasis-associated genes in pancreatic cancer. Cell Mol. Life Sci. 60 (2003) 1180-1199
3. Garcea G., Neal C.P., Pattenden C.J., Steward W.P., and Berry D.P. Molecular prognostic markers in pancreatic cancer: a systematic review. Eur. J. Cancer 41 (2005) 2213-2236
4. Hruban R.H. Pancreatic cancer: from genes to patient care. J. Gastrointest. Surg. 5 (2001) 583-587
5. Feurino L.W., Fisher W.E., Bharadwaj U., Yao Q., Chen C., and Li M. Current update of cytokines in pancreatic cancer: pathogenic mechanisms, clinical indication, and therapeutic values. Cancer Invest 24 (2006) 696-703
6. Balkwill F. Cancer and the chemokine network. Nat. Rev. Cancer 4 (2004) 540-550
7. Scotton C.J., Wilson J.L., Milliken D., Stamp G., and Balkwill F.R. Epithelial cancer cell migration: a role for chemokine receptors?,. Cancer Res. 61 (2001) 4961-4965
8. Strieter R.M., Burdick M.D., Gomperts B.N., Belperio J.A., and Keane M.P. CXC chemokines in angiogenesis. Cytokine Growth Factor Rev. 16 (2005) 593-609
9. Romagnani P., Lasagni L., Annunziato F., Serio M., and Romagnani S. CXC chemokines: the regulatory link between inflammation and angiogenesis. Trends Immunol. 25 (2004) 201-209
10. Ben Baruch A. The multifaceted roles of chemokines in malignancy. Cancer Metastasis Rev. 25 (2006) 357-371
11. Strieter R.M., Burdick M.D., Mestas J., Gomperts B., Keane M.P., and Belperio J.A. Cancer CXC chemokine networks and tumour angiogenesis. Eur. J. Cancer 42 (2006) 768-778
12. Hedin K.E. Chemokines: new, key players in the pathobiology of pancreatic cancer. Int. J. Gastrointest. Cancer 31 (2002) 23-29
13. Monti P., Marchesi F., Reni M., Mercalli A., Sordi V., Zerbi A., Balzano G., Di C., Allavena V.P., and Piemonti L. A comprehensive in vitro characterization of pancreatic ductal carcinoma cell line biological behavior and its correlation with the structural and genetic profile. Virchows Arch. 445 (2004) 236-247
14. Wente M.N., Keane M.P., Burdick M.D., Friess H., Buchler M.W., Ceyhan G.O., Reber H.A., Strieter R.M., and Hines O.J. Blockade of the chemokine receptor CXCR2 inhibits pancreatic cancer cell-induced angiogenesis. Cancer Lett. 241 (2006) 221-227
15. Kuwada Y., Sasaki T., Morinaka K., Kitadai Y., Mukaida N., and Chayama K. Potential involvement of IL-8 and its receptors in the invasiveness of pancreatic cancer cells. Int. J. Oncol. 22 (2003) 765-771
16. Shi Q., Abbruzzese J.L., Huang S., Fidler I.J., Xiong Q., and Xie K. Constitutive and inducible interleukin 8 expression by hypoxia and acidosis renders human pancreatic cancer cells more tumorigenic and metastatic. Clin. Cancer Res. 5 (1999) 3711-3721
17. Muller A., Homey B., Soto H., Ge N., Catron D., Buchanan M.E., McClanahan T., Murphy E., Yuan W., Wagner S.N., Barrera J.L., Mohar A., Verastegui E., and Zlotnik A. Involvement of chemokine receptors in breast cancer metastasis. Nature 410 (2001) 50-56
18. Zlotnik A. Chemokines and cancer. Int. J. Cancer 119 (2006) 2026-2029
19. Koshiba T., Hosotani R., Miyamoto Y., Ida J., Tsuji S., Nakajima S., Kawaguchi M., Kobayashi H., Doi R., Hori T., Fujii N., and Imamura M. Expression of stromal cell-derived factor 1 and CXCR4 ligand receptor system in pancreatic cancer: a possible role for tumor progression. Clin. Cancer Res. 6 (2000) 3530-3535
20. Wehler T., Wolfert F., Schimanski C.C., Gockel I., Herr W., Biesterfeld S., Seifert J.K., Adwan H., Berger M.R., Junginger T., Galle P.R., and Moehler M. Strong expression of chemokine receptor CXCR4 by pancreatic cancer correlates with advanced disease. Oncol. Rep. 16 (2006) 1159-1164
21. Hromas R., Broxmeyer H.E., Kim C., Nakshatri H., Christopherson K., Azam M., and Hou Y.H. Cloning of BRAK, a novel divergent CXC chemokine preferentially expressed in normal versus malignant cells. Biochem. Biophys. Res. Commun. 255 (1999) 703-706
22. Frederick M.J., Henderson Y., Xu X., Deavers M.T., Sahin A.A., Wu H., Lewis D.E., El Naggar A.K., and Clayman G.L. In vivo expression of the novel CXC chemokine BRAK in normal and cancerous human tissue. Am. J. Pathol. 156 (2000) 1937-1950
23. Schwarze S.R., Luo J., Isaacs W.B., and Jarrard D.F. Modulation of CXCL14 (BRAK) expression in prostate cancer. Prostate 64 (2005) 67-74
24. Ozawa S., Kato Y., Komori R., Maehata Y., Kubota E., and Hata R. BRAK/CXCL14 expression suppresses tumor growth in vivo in human oral carcinoma cells. Biochem. Biophys. Res. Commun. 348 (2006) 406-412
25. Kurth I., Willimann K., Schaerli P., Hunziker T., Clark-Lewis I., and Moser B. Monocyte selectivity and tissue localization suggests a role for breast and kidney-expressed chemokine (BRAK) in macrophage development. J. Exp. Med. 194 (2001) 855-861
26. Shellenberger T.D., Wang M., Gujrati M., Jayakumar A., Strieter R.M., Burdick M.D., Ioannides C.G., Efferson C.L., El Naggar A.K., Roberts D., Clayman G.L., and Frederick M.J. BRAK/CXCL14 is a potent inhibitor of angiogenesis and a chemotactic factor for immature dendritic cells. Cancer Res. 64 (2004) 8262-8270
27. Shurin G.V., Ferris R.L., Tourkova I.L., Perez L., Lokshin A., Balkir L., Collins B., Chatta G.S., and Shurin M.R. Loss of new chemokine CXCL14 in tumor tissue is associated with low infiltration by dendritic cells (DC), while restoration of human CXCL14 expression in tumor cells causes attraction of DC both in vitro and in vivo. J. Immunol. 174 (2005) 5490-5498
28. Starnes T., Rasila K.K., Robertson M.J., Brahmi Z., Dahl R., Christopherson K., and Hromas R. The chemokine CXCL14 (BRAK) stimulates activated NK cell migration: implications for the downregulation of CXCL14 in malignancy. Exp. Hematol. 34 (2006) 1101-1105
29. Allinen M., Beroukhim R., Cai L., Brennan C., Lahti-Domenici J., Huang H., Porter D., Hu M., Chin L., Richardson A., Schnitt S., Sellers W.R., and Polyak K. Molecular characterization of the tumor microenvironment in breast cancer. Cancer Cell 6 (2004) 17-32
30. Stein W.D., Litman T., Fojo T., and Bates S.E. A serial analysis of gene expression (SAGE) database analysis of chemosensitivity: comparing solid tumors with cell lines and comparing solid tumors from different tissue origins,. Cancer Res. 64 (2004) 2805-2816
31. Mahadevan D., and Von Hoff D.D. Tumor-stroma interactions in pancreatic ductal adenocarcinoma. Mol. Cancer Ther. 6 (2007) 1186-1197
32. Zhang H., Ma G., Dong M., Zhao M., Shen X., Ma Z., and Guo K. Epidermal growth factor promotes invasiveness of pancreatic cancer cells through NF-kappaB-mediated proteinase productions. Pancreas 32 (2006) 101-109
33. Duxbury M.S., and Whang E.E. RRM2 induces NF-kappaB-dependent MMP-9 activation and enhances cellular invasiveness. Biochem. Biophys. Res. Commun. 354 (2007) 190-196
34. Li L., Aggarwal B.B., Shishodia S., Abbruzzese J., and Kurzrock R. Nuclear factor-kappaB IkappaB kinase are constitutively active in human pancreatic cells and their down-regulation by curcumin (diferuloylmethane) is associated with the suppression of proliferation and the induction of apoptosis. Cancer 101 (2004) 2351-2362
35. Okami J., Nakamori S., Hiraoka N., Tsujie M., Hayashi N., Yamamoto H., Fujiwara Y., Nagano H., Dono K., Umeshita K., Sakon M., and Monden M. Suppression of pancreatic cancer cell invasion by a cyclooxygenase-2-specific inhibitor. Clin. Exp. Metastasis 20 (2003) 577-584
36. Peterson F.C., Thorpe J.A., Harder A.G., Volkman B.F., and Schwarze S.R. Structural determinants involved in the regulation of CXCL14/BRAK expression by the 26S proteasome. J. Mol. Biol. 363 (2006) 813-822